Glenmark aims to transform the treatment for Psoriasis in India
Mumbai, India; November 11, 2017: Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, announced the launch of Apremilast in India. Apremilast is the first advanced Oral Systemic treatment for Psoriasis in India. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor which is indicated for the treatment of moderate to severe Psoriasis. The launch of Apremilast will revolutionize the treatment of Psoriasis impacting close to 33 million Indians suffering from the condition.
Apremilast is an advanced oral treatment for Psoriasiswhich addresses the limitations of the current available therapies in India. Itacts in a targeted manner at an early stage of the disease progression. Also,it is an immunomodulator whereas the other available drugs in the country areimmunosuppressant including biologics and are mostly indicated for thetreatment of oncological conditions. Immunosuppressants suppress the immunesystem thereby making the body susceptible to various infections. Apremilastbeing an immunomodulator does not suppress the immune system and treats thecondition of psoriasis at an intracellular level which will benefit psoriasispatients across the country.
Apremilast is an oral therapy which can beself-administered unlike some of the currently available injectable therapywhich have to be administered by paramedics. Further, Apremilast is a saferdrug having no effects on other organs like the liver and kidney and does notrequire routine laboratory diagnostic tests like CBC, liver & Kidney testor TB screening as required in the case of other therapies used currently. Glenmark haslaunched Apremilast under the brand name ‘Aprezo’ indicated for the treatment of Psoriasis. Glenmark received approvalfrom DCGI for Apremilast after conductingclinical trials on the molecule as per the regulatory requirements.
Sujesh Vasudevan, President and Head – India,Middle East and Africa, “Glenmark isproud to be the first player to introduce Apremilast, an advanced oral and safetreatment for Psoriasis, in India. Glenmark has been in the field ofDermatology for 4 decades bringing advanced therapies to Indian patients. Withthe launch of Apremilast, we are aiming to transform the treatment paradigm formillions of Psoriasis patients in the country.” Rajesh Kapur, Senior Vice President – Sales& Marketing, Glenmark Pharmaceuticals, said, “Apremilast is a safer and efficacious treatmentcompared to the existing treatment available in the country. Apremilast is theonly oral medicine available in the country exclusively for Psoriasis. Inaddition to this, it also addresses the several limitations of existingtreatments like routine laboratory monitoring. We hope that millions ofpatients in India will now be able to live a better quality of life with thisrevolutionary treatment.”